---
res:
  bibo_abstract:
  - Over the last few decades, a large variety of nucleic acid‑based therapeutic approaches
    and drug formulations have been developed in the lab, tested in the clinic, and
    brought to market, ranging from antisense oligonucleotides (ASOs) and siRNAs to
    aptamer inhibitors and mRNA vaccines, with DNA and RNA nanostructure therapeutics
    already looming on the horizon. However, being susceptible toward hydrolysis,
    oxidation, non‑specific binding, and nuclease digestion, unmodified nucleic acids
    are rapidly degraded in vivo, resulting in poor therapeutic performance. Therefore,
    several stabilization strategies have been developed in order to protect those
    fragile molecules against adverse conditions during storage and in the body, while
    simultaneously accommodating their various mechanisms of action such as cellular
    uptake, target binding, or translation. These strategies include chemical modifications
    at the nucleoside level, complexation with proteins and polymers, and encapsulation
    in lipid nanoparticles (LNPs). Despite this variety of available methods, the
    field still faces many challenges, and this issue aims to provide an overview
    of the ongoing efforts to enhance the stability of therapeutic nucleic acids.@eng
  bibo_authorlist:
  - foaf_Person:
      foaf_givenName: Adrian Clemens
      foaf_name: Keller, Adrian Clemens
      foaf_surname: Keller
      foaf_workInfoHomepage: http://www.librecat.org/personId=48864
    orcid: 0000-0001-7139-3110
  bibo_doi: 10.18609/nai.2026.055
  bibo_issue: '6'
  bibo_volume: 3
  dct_date: 2026^xs_gYear
  dct_language: eng
  dct_title: Ongoing efforts to enhance stability@
...